IASO-782 in Autoimmune Hematological Diseases

Summary

This study is a randomized, double-blinded, and placebo-controlled phase Ia clinical study in subjects with autoimmune hematological diseases. The study is designed to assess the safety and tolerability of IASO-782 for the treatment of autoimmune haematological diseases (ITP and wAIHA).

Timeline

Start

2024-08-08

Primary completion

2027-10-09

Completion

2027-12-31

Drugs

Indications